> 首页 > 产品 > 一抗 > 其他 > Anti-PD-1 & VEGF Reference Antibody (Ivonescimab)

Anti-PD-1 & VEGF Reference Antibody (Ivonescimab)

Anti-PD-1 & VEGF Reference Antibody (Ivonescimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-PD-1 & VEGF Reference Antibody (Ivonescimab)is 98.33%, determined by SEC-HPLC.
Ivonescimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Ivonescimab bound to huPD-1-His, and the EC50 was 0.051 nM.
Ivonescimab bound to VEGFA protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Ivonescimab bound to huVEGFA-His, and the EC50 was 0.021 nM.
Ivonescimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Ivonescimab bound to huPD-1-Jurkat cells, and the EC50 was 6.274 nM.
Co-incubation of Ivonescimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Ivonescimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 7.957 nM.
Co-incubation of Ivonescimab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Ivonescimab can neutralize VEGF-165, and the IC50 was 7.957 nM.
The detected molecular weight of Anti-PD-1 & VEGF Reference Antibody (Ivonescimab) is 201.13 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q15116 & P15692
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-scFv

Additional Information
Target/Specificity	PDCD1 / PD-1 / CD279,VEGF
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.